Serhan Mohamed, Nilormi Adhiba, Ntacyabukura Blaise, Atkinson Katherine, Ducharme Robin, Hawken Steven, Ramsay Tim, Ang Joyce, Wilson Kumanan
Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Bruyère Health Research Institute, Bruyère Health, Ottawa, Ontario, Canada.
Hum Vaccin Immunother. 2025 Dec;21(1):2506286. doi: 10.1080/21645515.2025.2506286. Epub 2025 May 22.
On-time vaccination is essential for community protection against vaccine-preventable diseases. Insufficient on-time coverage and immunization series completion can put the population at risk. This study described individual coverage and series completion rates of the 12-month dose of pneumococcal, meningococcal, and measles-mumps-rubella (MMR) vaccines, as well as predictors of these rates in Canada. We conducted a cross-sectional study with immunization data from the pan-Canadian digital vaccination tool (CANImmunize) to evaluate coverage of the 12-month dose for single and multiple-dose vaccines. We conducted bivariate and multivariate logistic regression analyses to investigate associations between factors such as account holder gender, active integration of vaccine record with a public health unit (PHU) and inclusion of linked records in CANImmunize, with vaccination coverage. We calculated crude and adjusted odds ratios and 95% confidence intervals. We analyzed 60,890 records from children aged 13 months to 18 years. Coverage of the 12-month's dose of multiple-dose vaccines was significantly lower compared to single-dose vaccines. 14.28% versus 17.23% of children who had reported the first dose of pneumococcal and meningococcal vaccines, respectively, have not received the 12-month dose of the same vaccine. Additionally, 10-13.2% of children who received the 12-month dose of pneumococcal, meningococcal, and MMR vaccines received the vaccine late (13+ months). Based on our data, there is a gap in the coverage of the 12-month dose between single and multiple-dose vaccines, and the 12-month dose was delayed for a proportion of children. Reminder interventions targeting populations with identified predictors of sub-optimal coverage may be valuable.
按时接种疫苗对于社区预防疫苗可预防疾病至关重要。按时接种覆盖率不足和免疫系列完成率不足会使人群面临风险。本研究描述了加拿大肺炎球菌、脑膜炎球菌和麻疹-腮腺炎-风疹(MMR)疫苗12月龄剂量的个体接种覆盖率和系列完成率,以及这些比率的预测因素。我们利用全加拿大数字疫苗接种工具(CANImmunize)的免疫数据进行了一项横断面研究,以评估单剂量和多剂量疫苗12月龄剂量的接种覆盖率。我们进行了双变量和多变量逻辑回归分析,以调查诸如账户持有人性别、疫苗记录与公共卫生单位(PHU)的有效整合以及CANImmunize中链接记录的纳入等因素与疫苗接种覆盖率之间的关联。我们计算了粗比值比和调整后的比值比以及95%置信区间。我们分析了60890份13个月至18岁儿童的记录。多剂量疫苗12月龄剂量的接种覆盖率明显低于单剂量疫苗。分别报告了第一剂肺炎球菌和脑膜炎球菌疫苗的儿童中,有14.28%和17.23%未接种同一种疫苗的12月龄剂量。此外,接种肺炎球菌、脑膜炎球菌和MMR疫苗12月龄剂量的儿童中有10%-13.2%接种疫苗较晚(13个月以上)。根据我们的数据,单剂量和多剂量疫苗在12月龄剂量的接种覆盖率上存在差距,并且一部分儿童的12月龄剂量接种被推迟。针对具有次优覆盖率预测因素人群的提醒干预措施可能很有价值。